CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
MK-2206 +2 moredrug
Likely dose
MK-2206 135 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01235897
NCT01235897Phase 1Completed
CompareCT.gov

A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab

University of California, San Francisco·interventional·Posted Nov 8, 2010·Updated Apr 17, 2014

In Brief

A Phase 1 clinical trial evaluating MK-2206, Paclitaxel, and 1 other intervention for Advanced Solid Tumors and 2 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety and safest highest dose of an investigational drug called MK-2206 when given in combination with paclitaxel and trastuzumab in patients with Human Epidermal growth factor Receptor 2 (HER2)-overexpressing solid tumor malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Tumors, Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 8, 2010
Enrollment StartMar 1, 2011
Primary CompletionMar 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.7 years ago

Interventions

MK-2206drug

Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly

Paclitaxeldrug

80 mg/m2 weekly - paclitaxel

Trastuzumabdrug

2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab